We identified GLUD2, S100A12, and MMP9 as robust diagnostic biomarkers, with GLUD2 reflecting glutamate metabolism-related neural dysfunction in OSA and S100A12/MMP9 indicating cross-condition inflammatory processes in CADOSA. Here, MMP9 is linked to obstructive sleep apnea syndrome.